The reverse split and authorized share reduction are administrative actions to maintain OTC listing compliance and do not signal a change in business outlook. Monitor for any future capital raise or registration statement that may follow the newly authorized shelf capacity.
Price Chart
Executive Summary
Eloxx Pharmaceuticals filed an 8-K detailing a 1-for-11 reverse stock split and authorized share reduction from 500M to 100M, effective May 29, 2026. The filing also reports the exchange of 2.5M common shares for pre-funded warrants by existing investors (a non-dilutive restructuring of prior warrant exercises) and the appointment of two new independent directors. The reverse split is a mechanical adjustment to maintain OTC listing compliance and does not change the company's fundamental value.
Key Facts
- Board approved a 1-for-11 reverse stock split effective May 29, 2026; authorized shares reduced from 500M to 100M.
- Investors exchanged 2.5M shares of common stock for pre-funded warrants to purchase an equal number of shares at $0.01 per share (non-dilutive restructuring).
- Appointed Stephen W. Webster (former CFO of Spark Therapeutics) and Nina Kjellson (General Partner at Canaan Partners) as independent directors.
- Board size reduced from six to five directors.
- Stock continues trading on OTC Pink Sheets under symbol ELOX; new CUSIP 29014R301.
Financial Impact
No new capital raised; reverse split is a mechanical share consolidation with no change to market cap. The warrant exchange is neutral — shares were already issued and simply swapped for equivalent warrants.
Risk Factors
- Reverse split may reduce liquidity and increase volatility in the near term.
- The company remains on OTC Pink Sheets, indicating continued distress or low market interest.
- No financial data or guidance provided — fundamental outlook remains unclear.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-249692 |
| Document: d261568dex31.htm | 0001193125-26-249692 |
| Document: 0001193125-26-249692-index-headers.html | 0001193125-26-249692 |
| Document: 0001193125-26-249692-index.html | 0001193125-26-249692 |
| Document: 0001193125-26-249692.txt | 0001193125-26-249692 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 4d ago | 8-K | $13.12 | awaiting T+20 | — | $12.99 (−0.99%) |
Sep 21, 2026 5w ago | EFFECT | $17.19 $12.50 | ▼ −27.28% | ▼ −26.38% | $12.99 (−24.43%) |
Sep 11, 2026 6w ago | S-1 | $16.30 | awaiting T+20 | — | $12.99 (−20.31%) |
Jun 9, 2026 19w ago | EFFECT | $11.01 $10.95 | ▼ −0.55% | ▼ −1.99% | $12.99 (+17.98%) |
Jun 4, 2026 20w ago | S-1/A | $6.20 | awaiting T+20 | — | $12.99 (+109.52%) |
Jun 1, 2026 20w ago | S-1/A | $1.51 | awaiting T+20 | — | $12.99 (+760.26%) |
Jun 1, 2026 21w ago | 8-K | $4.07 $13.88 | ▲ +241.03% | ▲ +242.33% | $12.99 (+219.16%) |
May 7, 2026 24w ago | S-1 | $1.43 | awaiting T+20 | — | $12.99 (+807.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers